ScalesCD, SmithAC, HanleyJM, et al.Prevalence of kidney stones in the United States. Eur Urol, 2012; 62(1):160–165; doi: 10.1016/j.eururo.2012.03.052
2.
RuleAD, LieskeJC, LiX, et al.The ROKS nomogram for predicting a second symptomatic stone episode. J Am Soc Nephrol, 2014; 25(12):2878–2886; doi: 10.1681/ASN.2013091011
3.
PearleMS, GoldfarbDS, AssimosDG, et al.American Urological Assocation. Medical management of kidney stones: AUA Guideline. J Urol, 2014; 192(2):316–324; doi: 10.1016/j.juro.2014.05.006
4.
SkolarikosA, StraubM, KnollT, et al.Metabolic evaluation and recurrence prevention for urinary stone patients: EAU Guidelines. Eur Urol, 2015; 67(4):750–763; doi: 10.1016/j.eururo.2014.10.029
5.
SasDJ, HarrisPC, MillinerDS. Recent advances in the identification and management of inherited hyperoxalurias. Urolithiasis, 2019; 47(1):79–89; doi: 10.1007/s00240-018-1093-3
6.
KocvaraR, PlasguraP, PetríkA, et al.A prospective study of nonmedical prophylaxis after a first kidney stone. BJU Int, 1999; 84(4):393–398; doi: 10.1046/j.1464-410x.1999.00216.x
7.
HsiRS, YanPL, CrivelliJJ, et al.Comparison of selective vs empiric pharmacologic preventive therapy of kidney stone recurrence with high-risk features. Urology, 2022; 164:74–79; doi: 10.1016/j.urology.2021.12.037
8.
LotanY, CadedduJA, RoerhbornCG, et al.Cost-effectiveness of medical management strategies for nephrolithiasis. J Urol, 2004; 172(6 Pt 1):2275–2281; doi: 10.1097/01.ju.0000141498.11720.20
9.
PennistonKL, WertheimML, NakadaSY, et al.Factors associated with patient recall of individualized dietary recommendations for kidney stone prevention. Eur J Clin Nutr, 2016; 70(9):1062–1067; doi: 10.1038/ejcn.2016.79
10.
EisnerBH, ShethS, DretlerSP, et al.Abnormalities of 24-hour urine composition in first-time and recurrent stone-formers. Urology, 2012; 80(4):776–779; doi: 10.1016/j.urology.2012.06.034
11.
DauwCA, YiY, BierleinMJ, et al.Medication nonadherence and effectiveness of preventive pharmacological therapy for kidney stones. J Urol, 2016; 195(3):648–652; doi: 10.1016/j.juro.2015.10.082
12.
SabatéE. Adherence to long-term therapies: Evidence for action. World Health Organization: Geneva, Switzerland; 2003. Available from: https://apps.who.int/iris/handle/10665/42682 [Last accessed: August12, 2022].
13.
HsiRS, SanfordT, GoldfarbDS, et al.The role of the 24-hour urine collection in the prevention of kidney stone recurrence. J Urol, 2017; 197(4):1084–1089; doi: 10.1016/j.juro.2016.10.052
DaudonM, BouzidiH, BazinD. Composition and morphology of phosphate stones and their relation with etiology. Urol Res, 2010; 38(6):459–467; doi: 10.1007/s00240-010-0320-3
16.
TiseliusHG. Patients’ attitudes on how to deal with the risk of future stone recurrences. Urol Res, 2006; 34(4):255–260; doi: 10.1007/s00240-006-0056-2
17.
BensalahK, TuncelA, RamanJD, et al.How physician and patient perceptions differ regarding medical management of stone disease. J Urol, 2009; 182(3):998–1004; doi: 10.1016/j.juro.2009.05.025
18.
MiloseJC, KaufmanSR, HollenbeckBK, et al.Prevalence of 24-hour urine collection in high risk stone formers. J Urol, 2014; 191(2):376–380; doi: 10.1016/j.juro.2013.08.080
19.
DauwCA, AlruwailyAF, BierleinMJ, et al.Provider variation in the quality of metabolic stone management. Journal of Urology, 2015; 193(3):885–890; doi: 10.1016/j.juro.2014.09.111
20.
GhiraldiEM, BraitmanLE, FriedlanderJI. Factors associated with compliance with 24-hour urine collection. Urology, 2020; 142:65–69; doi: 10.1016/j.urology.2020.03.047
